Stereotaxis (STXS)
Market Price (11/6/2026): $0.99 | Market Cap: $99.2 MilSector: Health Care | Industry: Health Care Equipment
Stereotaxis (STXS)
Market Price (11/6/2026): $0.99Market Cap: $99.2 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Targeted Therapies, and Robotic Surgery. | Weak multi-year price returns2Y Excs Rtn is -81%, 3Y Excs Rtn is -114% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.18 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -23 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -76% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -5.5%, Rev Chg QQuarterly Revenue Change % is -13% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 29% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -51%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -52% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -25% Key risksSTXS key risks include [1] competition from simpler and faster alternative technologies that could negate its robotic advantages, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Targeted Therapies, and Robotic Surgery. |
| Weak multi-year price returns2Y Excs Rtn is -81%, 3Y Excs Rtn is -114% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.18 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -23 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -76% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -5.5%, Rev Chg QQuarterly Revenue Change % is -13% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 29% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -51%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -52% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -25% |
| Key risksSTXS key risks include [1] competition from simpler and faster alternative technologies that could negate its robotic advantages, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Stereotaxis (STXS) stock has lost about 15% since 7/31/2026 because of the following key factors:
1. Stereotaxis (STXS) experienced a significant revenue miss for fiscal Q2 2026 and a concerning decline in robotic system sales. The company reported fiscal Q2 2026 earnings on August 11, 2026, where revenue came in at $7.67 million, missing the consensus estimate of $8.35 million. Critically, system revenue for fiscal Q2 2026 fell to $1.5 million, with no robotic systems placed during the quarter, indicating a substantial weakness in a core revenue stream. Following this announcement, the stock price decreased by 4.11% on August 11, 2026. While recurring revenue saw a 7.5% year-over-year increase to $6.2 million with over $1 million in robotic catheter sales, this was overshadowed by the poor system sales performance.
2. Multiple analysts lowered their price targets for Stereotaxis following the disappointing fiscal Q2 2026 results. In August 2026, analysts from firms such as Lake Street and Citizens reduced their price targets for STXS from $4 to $3, while TD Cowen cut its target from $5 to $3. These downward revisions, occurring shortly after the Q2 earnings report, signaled diminished short-term growth expectations and likely contributed to negative investor sentiment, despite analysts generally maintaining a "Buy" rating for the stock.
Show more
Stereotaxis (STXS) stock has lost about 15% since 7/31/2026 because of the following key factors:
1. Stereotaxis (STXS) experienced a significant revenue miss for fiscal Q2 2026 and a concerning decline in robotic system sales. The company reported fiscal Q2 2026 earnings on August 11, 2026, where revenue came in at $7.67 million, missing the consensus estimate of $8.35 million. Critically, system revenue for fiscal Q2 2026 fell to $1.5 million, with no robotic systems placed during the quarter, indicating a substantial weakness in a core revenue stream. Following this announcement, the stock price decreased by 4.11% on August 11, 2026. While recurring revenue saw a 7.5% year-over-year increase to $6.2 million with over $1 million in robotic catheter sales, this was overshadowed by the poor system sales performance.
2. Multiple analysts lowered their price targets for Stereotaxis following the disappointing fiscal Q2 2026 results. In August 2026, analysts from firms such as Lake Street and Citizens reduced their price targets for STXS from $4 to $3, while TD Cowen cut its target from $5 to $3. These downward revisions, occurring shortly after the Q2 earnings report, signaled diminished short-term growth expectations and likely contributed to negative investor sentiment, despite analysts generally maintaining a "Buy" rating for the stock.
3. Persistent fundamental concerns and the anticipation of ongoing financial losses weighed on the stock. Beyond specific quarterly performance, Stereotaxis has faced broader challenges including "cash-flow risk, supply constraints on MAGiC, possible delays in product adoption and regulatory timing, and reliance on capital raises and key leadership." These fundamental issues contributed to a cautious outlook and continuous selling pressure, driving the stock near its 52-week low of $0.81 by early November 2026. Analysts expect Stereotaxis to report a loss of ($0.0533) per share for the upcoming fiscal Q3 2026, reinforcing concerns about profitability.
Show less
Stock Movement Drivers
Fundamental Drivers
The -16.7% change in STXS stock from 7/31/2026 to 11/5/2026 was primarily driven by a -12.5% change in the company's P/S Multiple.| (LTM values as of) | 7312026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.26 | 1.05 | -16.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 31 | 30 | -3.6% |
| P/S Multiple | 4.0 | 3.5 | -12.5% |
| Shares Outstanding (Mil) | 99 | 100 | -1.1% |
| Cumulative Contribution | -16.7% |
Market Drivers
7/31/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| STXS | -16.7% | |
| Market (SPY) | -1.9% | 10.5% |
| Sector (XLV) | 13.8% | 7.2% |
Fundamental Drivers
The -43.9% change in STXS stock from 4/30/2026 to 11/5/2026 was primarily driven by a -37.0% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.87 | 1.05 | -43.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 30 | -7.1% |
| P/S Multiple | 5.5 | 3.5 | -37.0% |
| Shares Outstanding (Mil) | 96 | 100 | -4.0% |
| Cumulative Contribution | -43.9% |
Market Drivers
4/30/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| STXS | -43.9% | |
| Market (SPY) | 2.3% | 23.7% |
| Sector (XLV) | 27.2% | 6.0% |
Fundamental Drivers
The -63.9% change in STXS stock from 10/31/2025 to 11/5/2026 was primarily driven by a -56.6% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.91 | 1.05 | -63.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 30 | -5.5% |
| P/S Multiple | 8.0 | 3.5 | -56.6% |
| Shares Outstanding (Mil) | 88 | 100 | -12.1% |
| Cumulative Contribution | -63.9% |
Market Drivers
10/31/2025 to 11/5/2026| Return | Correlation | |
|---|---|---|
| STXS | -63.9% | |
| Market (SPY) | 8.4% | 33.3% |
| Sector (XLV) | 29.8% | 17.3% |
Fundamental Drivers
The -30.5% change in STXS stock from 10/31/2023 to 11/5/2026 was primarily driven by a -19.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312023 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.51 | 1.05 | -30.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 29 | 30 | 2.4% |
| P/S Multiple | 4.2 | 3.5 | -16.2% |
| Shares Outstanding (Mil) | 81 | 100 | -19.0% |
| Cumulative Contribution | -30.5% |
Market Drivers
10/31/2023 to 11/5/2026| Return | Correlation | |
|---|---|---|
| STXS | -30.5% | |
| Market (SPY) | 81.3% | 29.7% |
| Sector (XLV) | 55.5% | 19.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| STXS Return | 22% | -67% | -15% | 30% | 1% | -54% | -79% |
| Peers Return | 30% | -7% | 2% | -6% | 2% | 26% | 50% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| STXS Win Rate | 50% | 25% | 58% | 42% | 50% | 36% | |
| Peers Win Rate | 71% | 48% | 58% | 52% | 43% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 45% | |
Max Drawdowns [4] | |||||||
| STXS Max Drawdown | -49% | -77% | -48% | -46% | -41% | -70% | |
| Peers Max Drawdown | -19% | -41% | -38% | -45% | -34% | -32% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: EW, ATRC, UFPT, IART, KMTS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/5/2026 (YTD)
How Low Can It Go
| Event | STXS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.5% | -18.8% |
| % Gain to Breakeven | 41.9% | 23.1% |
| Time to Breakeven | 56 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -38.5% | -6.7% |
| % Gain to Breakeven | 62.6% | 7.1% |
| Time to Breakeven | 215 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.7% | -33.7% |
| % Gain to Breakeven | 154.2% | 50.9% |
| Time to Breakeven | 78 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -34.7% | -12.2% |
| % Gain to Breakeven | 53.1% | 13.9% |
| Time to Breakeven | 30 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -80.0% | -6.8% |
| % Gain to Breakeven | 400.0% | 7.3% |
| Time to Breakeven | 1323 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -28.7% | -0.2% |
| % Gain to Breakeven | 40.3% | 0.2% |
| Time to Breakeven | 21 days | 1 days |
In The Past
Stereotaxis's stock fell -29.5% during the 2025 US Tariff Shock. Such a loss loss requires a 41.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | STXS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.5% | -18.8% |
| % Gain to Breakeven | 41.9% | 23.1% |
| Time to Breakeven | 56 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -38.5% | -6.7% |
| % Gain to Breakeven | 62.6% | 7.1% |
| Time to Breakeven | 215 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.7% | -33.7% |
| % Gain to Breakeven | 154.2% | 50.9% |
| Time to Breakeven | 78 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -34.7% | -12.2% |
| % Gain to Breakeven | 53.1% | 13.9% |
| Time to Breakeven | 30 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -80.0% | -6.8% |
| % Gain to Breakeven | 400.0% | 7.3% |
| Time to Breakeven | 1323 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -28.7% | -0.2% |
| % Gain to Breakeven | 40.3% | 0.2% |
| Time to Breakeven | 21 days | 1 days |
In The Past
Stereotaxis's stock fell -29.5% during the 2025 US Tariff Shock. Such a loss loss requires a 41.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Stereotaxis (STXS)
Stereotaxis, Inc. develops, manufactures, and markets robotic systems, instruments, and information solutions primarily for complex interventional procedures within the interventional laboratory, particularly those involving the heart and blood vessels. Their core technology, Robotic Magnetic Navigation (RMN), allows physicians to precisely guide catheters and guidewires through the blood vessels and chambers of the heart to treatment sites, enhancing precision and potentially improving outcomes for patients.
The company's main offerings include its Genesis RMN and Niobe robotic magnetic navigation systems, which form the cornerstone of its technology. Complementing these systems are specialized diagnostic and ablation catheters like CARTO RMT and NAVISTAR RMT, along with disposables such as QuikCAS for automated catheter advancement. Stereotaxis also provides the Odyssey information system for real-time procedure management and the Stereotaxis Imaging Model S X-ray system for imaging within the robotic interventional operating room. Additionally, their Vdrive system offers enhanced navigation and stability for various interventional devices.
Stereotaxis primarily serves interventional laboratories globally, targeting physicians who perform intricate procedures, often in electrophysiology and structural heart interventions. By providing advanced robotic tools and integrated solutions, the company aims to improve the safety, efficacy, and reproducibility of these complex medical interventions, ultimately benefiting both medical professionals and patients.
AI Analysis | Feedback
Here are 1-3 brief analogies for Stereotaxis (STXS):
- Intuitive Surgical for heart catheter procedures.
- Garmin for guiding medical devices inside the human body with robotic precision.
AI Analysis | Feedback
Here are the major products of Stereotaxis (STXS):
- Genesis RMN and Niobe Systems: Robotic magnetic navigation (RMN) systems that enable image-guided delivery of catheters and guidewires for complex interventional procedures.
- Odyssey: A real-time information solution designed to manage, control, record, and share interventional procedures across networks.
- Stereotaxis Imaging Model S X-ray System: A comprehensive single-plane X-ray system for robotic interventional operating rooms, including a c-arm, powered table, and high-definition monitors.
- Electrophysiology Catheters and Disposables: This category includes QuikCAS automated catheter advancement disposables and various steerable tip diagnostic/ablation catheters such as the CARTO RMT, CELSIUS RMT, and NAVISTAR RMT series.
- Vdrive System: A system providing navigation and stability for diagnostic and therapeutic devices, complemented by disposable components like V-Loop, V-Sono, and V-CAS.
- Magnetic Ablation Catheter (in development): A magnetic ablation catheter being developed in collaboration with Osypka AG, leveraging Stereotaxis' robotic technology.
AI Analysis | Feedback
AI Analysis | Feedback
- Johnson & Johnson (JNJ)
- TTM Technologies, Inc. (TTM)
- Osypka AG
AI Analysis | Feedback
David L. Fischel, Chairman and Chief Executive Officer
David Fischel became a Director of Stereotaxis in September 2016, and assumed the roles of CEO and Chairman in February 2017. Prior to joining Stereotaxis, he spent over eight years as a Principal and portfolio manager, focusing on medical device investments at DAFNA Capital Management, LLC. Before DAFNA Capital, he worked as a research analyst at SCP Vitalife, a healthcare venture capital fund. Mr. Fischel holds a B.S. magna cum laude in Applied Mathematics from UCLA and an MBA from Bar-Ilan University. He is also a Certified Public Accountant (CPA), Chartered Financial Analyst (CFA), and Chartered Alternative Investment Analyst (CAIA). His career includes a transition from an investor to an operator within the medical device space.
Kimberly Peery, Chief Financial Officer
Kimberly Peery was appointed Chief Financial Officer of Stereotaxis, effective October 1, 2019. She initially joined the company in 2003 and previously held the position of Vice President of Finance. Before her tenure at Stereotaxis, Ms. Peery gained experience as a controller at various private companies. She is a Certified Public Accountant and earned both a Bachelor of Science in Accounting and a Master of Science in Accounting and Computer Science from Southern Illinois University, Edwardsville.
Patricia Williams, General Counsel
Patricia Williams joined Stereotaxis in 2025. She brings over two decades of legal experience from significant healthcare and publicly traded companies, including roles at Peabody Energy (NYSE: BTU), the integrated healthcare system SSM Health, RehabCare Group (acquired by Kindred Healthcare), and Thermadyne Holdings (NSDQ: THC).
Keith Galloway, Vice President of Operations
Keith Galloway became part of the Stereotaxis team in 2010 and was promoted to Vice President of Operations in September 2019. He has more than 15 years of experience, specializing in strategy and financial analytics. Prior to Stereotaxis, he completed an Executive Development Program and worked as a Senior Financial Analyst at Anheuser Busch/InBev. Mr. Galloway is a CFA Charterholder and holds a bachelor's degree in Mechanical Engineering and an MBA in Finance and Marketing from Washington University in St. Louis.
Casey Payne, Vice President, APAC Sales & Global Training
Casey Payne leads Stereotaxis' commercial teams in the Asia Pacific region and also oversees Global Training. Before joining Stereotaxis, he held commercial positions at Genentech. Mr. Payne earned his B.S. in Systems Engineering from the United States Military Academy at West Point and an MBA from the University of North Carolina at Chapel Hill.
AI Analysis | Feedback
-
Financial Health and Cash Burn
Stereotaxis faces significant financial challenges, including poor financial strength ratings, high debt levels, and persistent operating losses that lead to a high cash burn rate. The company's balance sheet has been described as weak, with limited cash reserves and a short cash runway, necessitating potential future capital raises that could dilute existing shareholders. Some analyses have placed the company in a "distress zone," indicating a potential risk to its continued operations. -
Regulatory Delays and Commercial Adoption
The company's ability to grow revenue and achieve profitability is highly dependent on timely regulatory approvals for its new products, such as Genesis X and MAGiC catheters. Delays in obtaining these approvals can significantly push back commercialization timelines. Furthermore, even with approvals, the adoption of Stereotaxis's robotic systems and disposables by hospitals faces hurdles due to lengthy purchasing cycles, the substantial capital expenditure required, and the need for clear demonstrations of clinical and cost benefits. -
Competitive Landscape and Market Acceptance of Robotic Navigation
While Stereotaxis is a pioneer and leader in robotic magnetic navigation, it operates within a broader medical device industry, particularly the electrophysiology market, that is dominated by larger, established companies. The company faces ongoing competition from new robotic platforms and improved manual catheter offerings from these major players. The long-term success of Stereotaxis's business also hinges on the broader market acceptance and increased utilization of robotic magnetic navigation in interventional procedures.
AI Analysis | Feedback
AI Analysis | Feedback
- Robotic Magnetic Navigation (RMN) Systems: The global Robotic Magnetic Navigation (RMN) System market is projected to reach an estimated $518 million by 2025, with an anticipated expansion to between $500 million and $700 million by the end of the forecast period (within 5-7 years from 2025).
- Electrophysiology (EP) Ablation Market (including ablation catheters and related systems/disposables): The global electrophysiology ablation market was valued at USD 7.17 billion in 2025 and is projected to grow to approximately USD 21.86 billion by 2035. More specifically, the global electrophysiology ablation catheters market was valued at $4.11 billion in 2025 and is expected to reach $7.83 billion by 2029. Another perspective on this segment, the global cardiac ablation market, was valued at USD 5.8 billion in 2025 and is projected to grow to USD 20 billion by 2035.
- Stereotaxis Imaging Model S X-ray System: The global Stereotactic X-Ray Market, which includes such systems, is projected to reach USD 2.1 billion by 2030, increasing from USD 1.4 billion in 2024.
AI Analysis | Feedback
Stereotaxis (STXS) is poised for future revenue growth over the next two to three years, driven by the increasing adoption of its robotic systems, the expansion of its disposable catheter portfolio, the introduction of new technologies, and strategic market initiatives.
Here are 3-5 expected drivers of future revenue growth for Stereotaxis:
- Increasing Adoption and Global Expansion of Genesis RMN and GenesisX Robotic Systems: Stereotaxis expects continued double-digit revenue growth in 2026, supported by increased production capabilities and commercial adoption of its Genesis RMN and the next-generation GenesisX robotic systems. The GenesisX system, which offers enhanced accessibility due to smaller magnets and integrated magnetic shielding, has already secured its first order and received regulatory approvals in the United States, Europe, and China, indicating significant potential for broader market penetration. Furthermore, successful initial procedures with the Genesis RMN system in prominent cardiac centers, such as Erasmus University Medical Center in the Netherlands and Corewell Health in Michigan, are fostering clinical confidence and encouraging wider adoption globally.
- Growth in Recurring Revenue from Disposable Catheters, Particularly the MAGiC Line: A significant portion of Stereotaxis's revenue growth is anticipated from its recurring streams, primarily driven by the sales of disposable catheters, especially the MAGiC ablation catheter line. The MAGiC ablation catheter has received CE Mark approval in Europe and regulatory approvals in the U.S. and Europe for MAGiC and MAGiC Sweep high-density mapping catheter, paving the way for broad adoption among robotic users. Clinical experience with MAGiC in ongoing European studies further supports expectations for its increased utilization, contributing substantially to recurring revenue.
- Introduction of Innovative New Products and Technologies: Stereotaxis is expanding its product portfolio with advanced technologies designed to enhance interventional procedures. The company plans to launch MAGiC with Pulse Field Ablation in Europe by the end of 2025, which is expected to boost revenue potential through new product marketing. Additionally, Stereotaxis is investing in its Synchrony digital surgery suite technology, with anticipated FDA clearance and projected revenue exceeding $3 million from initial demand in 2026, further diversifying its revenue streams.
- Strategic Collaborations and Evolving Commercial Models: Strategic partnerships and a refined commercial approach are expected to drive revenue growth. The ongoing collaboration with Osypka AG for the development and manufacturing of a next-generation magnetic ablation catheter, fully owned by Stereotaxis, underpins the company's proprietary catheter offerings. The successful integration of Abbott's EnSite X EP System with Stereotaxis's Robotic Magnetic Navigation System also represents a significant step, combining advanced cardiac mapping with robotic precision to improve arrhythmia treatment, potentially increasing the adoption of Stereotaxis's technology in electrophysiology labs. Moreover, Stereotaxis is transitioning to a more attractive commercial model, blending sales, leases, and placements funded by disposable commitments, which is designed to enhance revenue potential and encourage broader adoption by healthcare providers.
AI Analysis | Feedback
Share Issuance
- Stereotaxis has experienced a consistent increase in its shares outstanding over the last three to five years, rising from approximately 73 million in Q4 2020 to 92 million in Q4 2025.
- The company's shares outstanding increased from 75.8 million in 2021 to 92.01 million in 2025.
- Stereotaxis has a Sales Agreement with Roth Capital Partners, LLC, facilitating at-the-market offerings of common stock under an effective shelf registration statement on Form S-3.
Capital Expenditures
- Capital expenditures for Stereotaxis totaled -$93,000 in the last 12 months reported as of March 15, 2026.
- In the third quarter of 2025, capital expenditures were $0.000 million, marking a 100% decrease from the previous quarter.
Peer Outperformance in Health Care Equipment
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| STXS | Stereotaxis | 3.1% | -4.7x | -62.6% | -39.3% | -82.8% | — |
| ITGR | Integer | 6.8% | 41.6x | 86.0% | 46.5% | 40.0% | +123pp |
| ABT | Abbott Laboratories | 6.5% | 41.9x | -6.5% | 27.4% | 0.9% | +84pp |
| MDT | Medtronic | 6.0% | 25.6x | 19.8% | 57.5% | 0.0% | +83pp |
| RVTY | Revvity | 0.9% | 70.8x | 63.3% | 77.7% | -9.6% | +73pp |
| ZBH | Zimmer Biomet | 5.6% | 26.5x | 23.4% | 0.6% | -19.1% | +64pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 7.6% | 56.6% | 93.6% | CAH 498% · MCK 396% · COR 181% |
| Health Care Services | 20 | 33.8% | 28.8% | 6.1% | HIMS 189% · RDNT 125% · DGX 100% |
| Health Care Facilities | 25 | 13.9% | 27.4% | -1.4% | THC 280% · NHC 210% · EHC 186% |
| Managed Health Care | 8 | 47.9% | 1.6% | -2.2% | OSCR 95% · HQY 52% · ELV 10% |
| Health Care Equipment ← | 50 | 11.0% | 17.8% | -17.6% | UFPT 355% · GKOS 286% · PLSE 127% |
| Pharmaceuticals | 61 | -12.9% | 10.6% | -37.3% | LQDA 977% · XERS 571% · KNSA 500% |
| Health Care Supplies | 11 | 23.9% | 17.0% | -40.1% | LNTH 248% · HAE 66% · MMSI 29% |
| Life Sciences Tools & Services | 108 | -8.1% | -18.9% | -74.5% | AXGN 255% · NTRA 214% · MEDP 181% |
| Biotechnology | 364 | -25.8% | -36.1% | -82.0% | ELVN 1073% · TRVI 995% · DNTH 956% |
| Health Care Technology | 21 | -21.4% | -50.4% | -82.8% | VEEV -3% · DOCS -51% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Stereotaxis Earnings Notes | 12/16/2025 | |
| How Low Can Stereotaxis Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 44.77 |
| Mkt Cap | 2.2 |
| Rev LTM | 632 |
| Op Inc LTM | 73 |
| FCF LTM | 61 |
| FCF 3Y Avg | 32 |
| CFO LTM | 72 |
| CFO 3Y Avg | 69 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.3% |
| Rev Chg 3Y Avg | 14.7% |
| Rev Chg Q | 10.5% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Inc Chg LTM | 18.7% |
| Op Inc Chg 3Y Avg | 20.4% |
| Op Mgn LTM | 4.4% |
| Op Mgn 3Y Avg | 2.7% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 11.3% |
| CFO/Rev 3Y Avg | 7.6% |
| FCF/Rev LTM | 8.0% |
| FCF/Rev 3Y Avg | 3.6% |
Price Behavior
| Market Price | $1.05 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -63.2% | |
| 50 Days | 200 Days | |
| DMA Price | $1.18 | $1.67 |
| DMA Trend | down | down |
| Distance from DMA | -11.0% | -37.3% |
| 3M | 1YR | |
| Volatility | 54.8% | 54.3% |
| Downside Capture | 200.40 | 258.47 |
| Upside Capture | -32.83 | 98.17 |
| Correlation (S&P 500) | 29.5% | 42.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.89 | 1.19 | 1.58 | 1.57 | 1.67 | 1.25 |
| Up Beta | 2.50 | 1.85 | 3.22 | 2.31 | 2.08 | 1.04 |
| Down Beta | 0.62 | 2.27 | 1.92 | 1.96 | 1.32 | 1.16 |
| Up Capture | -204% | -92% | 12% | 15% | 71% | 155% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 4 | 12 | 22 | 48 | 105 | 334 |
| Down Capture | 303% | 268% | 216% | 196% | 165% | 111% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 14 | 25 | 34 | 66 | 129 | 365 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STXS | |
|---|---|---|---|---|
| STXS | -61.3% | 54.3% | -1.55 | - |
| Sector ETF (XLV) | 29.2% | 16.9% | 1.33 | 17.5% |
| Equity (SPY) | 9.5% | 13.6% | 0.41 | 33.2% |
| Gold (GLD) | 3.6% | 28.7% | 0.11 | 29.2% |
| Commodities (DBC) | 37.7% | 21.2% | 1.40 | -16.5% |
| Real Estate (VNQ) | 12.0% | 14.2% | 0.55 | 19.2% |
| Bitcoin (BTCUSD) | -20.8% | 43.3% | -0.42 | 33.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STXS | |
|---|---|---|---|---|
| STXS | -29.0% | 65.8% | -0.25 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.36 | 22.7% |
| Equity (SPY) | 11.3% | 17.3% | 0.48 | 31.1% |
| Gold (GLD) | 17.5% | 19.1% | 0.74 | 10.6% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | -2.8% |
| Real Estate (VNQ) | 1.2% | 18.9% | -0.05 | 22.0% |
| Bitcoin (BTCUSD) | 5.9% | 51.5% | 0.29 | 20.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with STXS | |
|---|---|---|---|---|
| STXS | -6.5% | 71.2% | 0.18 | - |
| Sector ETF (XLV) | 12.2% | 16.8% | 0.60 | 22.4% |
| Equity (SPY) | 14.9% | 18.0% | 0.70 | 28.5% |
| Gold (GLD) | 12.0% | 16.5% | 0.59 | 8.2% |
| Commodities (DBC) | 7.6% | 18.1% | 0.33 | 5.0% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | 24.1% |
| Bitcoin (BTCUSD) | 61.3% | 66.2% | 1.01 | 17.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/14/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | -4.1% | -6.8% | -11.0% |
| 5/12/2026 | -3.6% | -9.9% | -5.2% |
| 3/9/2026 | -4.8% | -7.7% | -6.8% |
| 11/12/2025 | -14.7% | -19.6% | -16.8% |
| 8/7/2025 | 14.2% | 32.4% | 31.5% |
| 5/12/2025 | 1.9% | 1.0% | 7.2% |
| 3/3/2025 | -5.8% | -9.2% | -14.6% |
| 11/12/2024 | 22.2% | 8.1% | 21.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 13 |
| # Negative | 15 | 15 | 11 |
| Median Positive | 13.4% | 9.9% | 21.1% |
| Median Negative | -5.8% | -9.2% | -14.6% |
| Max Positive | 32.3% | 32.4% | 40.9% |
| Max Negative | -26.5% | -30.4% | -29.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | -4.1% | -6.8% | -11.0% |
| 5/12/2026 | -3.6% | -9.9% | -5.2% |
| 3/9/2026 | -4.8% | -7.7% | -6.8% |
| 11/12/2025 | -14.7% | -19.6% | -16.8% |
| 8/7/2025 | 14.2% | 32.4% | 31.5% |
| 5/12/2025 | 1.9% | 1.0% | 7.2% |
| 3/3/2025 | -5.8% | -9.2% | -14.6% |
| 11/12/2024 | 22.2% | 8.1% | 21.1% |
| 8/12/2024 | 11.7% | 6.1% | 21.1% |
| 5/13/2024 | -3.2% | -3.2% | -10.2% |
| 3/4/2024 | -6.9% | -1.9% | 13.0% |
| 11/9/2023 | -10.7% | -15.4% | 16.0% |
| 8/10/2023 | 13.4% | 9.9% | 19.0% |
| 5/9/2023 | -1.7% | -4.5% | 21.6% |
| 3/3/2023 | -6.2% | -16.9% | -21.5% |
| 11/10/2022 | 4.1% | 26.2% | 17.4% |
| 8/9/2022 | -18.7% | -3.5% | -23.7% |
| 5/10/2022 | -5.0% | -10.9% | 10.4% |
| 3/3/2022 | -26.5% | -29.8% | -22.3% |
| 11/12/2021 | -3.3% | -3.4% | -12.9% |
| 8/10/2021 | -21.3% | -30.4% | -29.3% |
| 5/10/2021 | 6.6% | 2.2% | 31.9% |
| 2/25/2021 | 32.3% | 32.1% | 22.5% |
| 11/9/2020 | 23.2% | 23.2% | 40.9% |
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 13 |
| # Negative | 15 | 15 | 11 |
| Median Positive | 13.4% | 9.9% | 21.1% |
| Median Negative | -5.8% | -9.2% | -14.6% |
| Max Positive | 32.3% | 32.4% | 40.9% |
| Max Negative | -26.5% | -30.4% | -29.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/12/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/12/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/10/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/13/2021 | 10-Q |
| 12/31/2020 | 03/12/2021 | 10-K |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/16/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
Recent Forward Guidance
Updated 11/2/2026Latest: Q2 2026 Earnings Reported 8/11/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Recurring Revenue | Reported | 7.00 Mil | -30.0% | Lowered | Guidance: 10.00 Mil for Q3 2026 | |||
| Q3 2026 System Revenue | Reported | 3.00 Mil | ||||||
| Q4 2026 Recurring Revenue | Reported | 8.00 Mil | -20.0% | Lowered | Guidance: 10.00 Mil for Q4 2026 | |||
| Q4 2026 System Revenue | Reported | 3.00 Mil | ||||||
Prior: Q1 2026 Earnings Reported 5/12/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Revenue | Reported | 10.00 Mil | ||||||
| Q4 2026 Revenue | Reported | 10.00 Mil | ||||||
| 2026 Catheter Manufacturing Rate | Reported | 500 | ||||||
| 2026 Revenue | Reported | 40.00 Mil | 0 | Affirmed | Guidance: 40.00 Mil for 2026 | |||
Q4 2025 Earnings Reported 3/9/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 40.00 Mil | 0 | Affirmed | Guidance: 40.00 Mil for 2026 | |||
| 2026 Revenue Growth | Reported | 10.0% | ||||||
| 2026 Synchrony Digital Surgery Suite Revenue | Reported | 3.00 Mil | ||||||
Q3 2025 Earnings Reported 11/12/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Revenue | Reported | 9.00 Mil | -5.3% | Lowered | Guidance: 9.50 Mil for Q4 2025 | |||
| Q4 2025 System Revenue | Reported | 3.00 Mil | 20.0% | Raised | Guidance: 2.50 Mil for Q4 2025 | |||
| Q4 2025 Recurring Revenue | Reported | 6.00 Mil | -14.3% | Lowered | Guidance: 7.00 Mil for Q4 2025 | |||
| 2025 Revenue Growth | Reported | 20.0% | ||||||
| 2026 Quarterly Revenue | Reported | 10.00 Mil | ||||||
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.